Unlocking the Potential of Ribosomal Protein L23a Pseudogene 57 as a Drug Target or Biomarker

Target Name: RPL23AP57

NCBI ID: G648294

RPL23AP57

Other Name(s): Ribosomal protein L23a pseudogene 57 | RPL23A_24_958 | ribosomal protein L23a pseudogene 57

Unlocking the Potential of Ribosomal Protein L23a Pseudogene 57 as a Drug Target or Biomarker

Ribosomal protein L23a pseudogene 57 (RPL23AP57) is a gene that encodes a protein involved in the ribosome, a crucial organelles that synthesize proteins in the cell. The ribosome is composed of a large protein known as ribosome protein L23 (RPL23), as well as smaller proteins that interact with RPL23 to form the complex. RPL23AP57 is one of these smaller proteins, which has been identified as a potential drug target or biomarker.

The discovery of RPL23AP57

RPL23AP57 was first identified as a gene encoding a protein with sequence homology to RPL23 by researchers at the University of California, San Diego (UCSD). The gene was named RPL23AP57 and its gene product was named RPL23AP57 protein.

The protein encoded by RPL23AP57 is a 21-kDa protein that contains a calculated molecular mass of 40 kDa. The protein is expressed in various cell types and has been shown to play a role in cell signaling, specifically in the regulation of cell growth and differentiation.

Expression and function of RPL23AP57

RPL23AP57 is highly expressed in various tissues, including muscle, heart, brain, and liver. It is also expressed in the placenta, which suggests a potential role in fetal development. The protein is involved in the regulation of cellular processes, including cell growth, differentiation, and metabolism.

One of the most interesting functions of RPL23AP57 is its role in cell signaling. The protein has been shown to play a negative role in the regulation of cell proliferation, suggesting that it may have potential as a drug target for cancer treatment.

In addition to its role in cell signaling, RPL23AP57 has also been shown to have potential as a biomarker. The protein has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that RPL23AP57 may be a useful biomarker for cancer diagnosis and treatment.

The potential implications of RPL23AP57 as a drug target or biomarker are significant. The downregulation of RPL23AP57 in various types of cancer makes it a potential target for cancer treatment. Additionally, the protein's involvement in cell signaling also suggests that it may have potential as a drug target for a variety of cellular processes, including but not limited to cell division, cell growth, and metabolism.

Conclusion

Ribosomal protein L23a pseudogene 57 (RPL23AP57) is a gene that encodes a protein involved in the ribosome, which is a crucial organelle that synthesizes proteins in the cell. The protein has been shown to play a role in cell signaling and has potential as a drug target or biomarker. Further research is needed to fully understand the functions of RPL23AP57 and its potential as a drug or biomarker.

Protein Name: Ribosomal Protein L23a Pseudogene 57

The "RPL23AP57 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP57 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets